UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 23, 2006
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 0-19700 |
| 33-0266089 |
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of incorporation) |
| File Number) |
| Identification No.) |
9360 Towne Centre Drive |
|
| ||
San Diego, California |
| 92121 | ||
(Address of principal executive offices) |
| (Zip Code) | ||
Registrant’s telephone number, including area code: (858) 552-2200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On March 23, 2006, Amylin Pharmaceuticals, Inc. issued a press release announcing that, following discussions with the U.S. Food and Drug Administration, a long-term comparator clinical study of a long-acting release formulation of BYETTA® (exenatide) injection in patients with type 2 diabetes has been initiated. This study is designed to generate the type of safety and efficacy data that could form the basis of a New Drug Application. A copy of this press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press release issued by Amylin on March 23, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMYLIN PHARMACEUTICALS, INC. | |
|
|
|
Dated: March 24, 2006 | By: | /S/ LLOYD A. ROWLAND |
|
| Lloyd A. Rowland |
|
| Vice President, Legal, General Counsel and |
|
| Secretary |
2
Exhibit Index
Exhibit No. |
|
|
|
|
|
99.1 |
| Press release issued by Amylin on March 23, 2006. |
3
